CHWY Insider Filing: Satish Mehta 10b5-1 Sale and Outstanding RSUs/PRSUs
Rhea-AI Filing Summary
Satish Mehta, Chief Technology Officer of Chewy, Inc. (CHWY), reported a sale of 46,765 shares of Class A common stock on 09/15/2025 at a price of $34.69 per share under a Rule 10b5-1 trading plan adopted April 9, 2025. Following the reported transaction, the filing lists 229,702 shares of Class A common stock beneficially owned directly. The filing also discloses multiple outstanding restricted stock units and performance-based restricted stock units (PRSUs): PRSUs from April 6, 2023 that vested performance certification on March 22, 2024 (vesting on February 1, 2026); RSUs from April 6, 2023 with staggered vesting beginning February 1, 2026; PRSUs from April 4, 2024 certified on March 26, 2025 (vesting February 1, 2027); and RSUs granted April 8, 2025 and April 4, 2024 with specified time-based vesting schedules.
Positive
- Transaction executed under a Rule 10b5-1 trading plan, indicating preplanned and compliant insider selling.
- Performance conditions for PRSUs were certified (March 22, 2024 and March 26, 2025), clarifying achievement of stated goals.
- Detailed vesting schedules disclosed for multiple RSU and PRSU grants, improving transparency on future dilution timing.
Negative
- Insider sale of 46,765 shares was reported, which reduces the reporting person's direct shareholdings.
- Beneficial ownership after the sale remains concentrated in equity awards, indicating future dilution when RSUs/PRSUs vest.
Insights
TL;DR: Routine, preplanned insider sale with disclosed equity awards and certified performance RSUs; no unusual governance red flags in this filing.
The Form 4 shows a single open-market sale of 46,765 Class A shares executed under a Rule 10b5-1 trading plan, indicating the transaction was pre-authorized and aimed to provide an affirmative defense to insider trading claims. The report clearly discloses the reporting persons role as CTO and details multiple RSU and PRSU grants with certification dates and vesting schedules, which supports transparency around executive compensation timing. This filing appears procedural and compliant, providing investors clarity on outstanding equity awards and the mechanics of the reported sale.
TL;DR: Compensation-related disclosures show performance conditions were met for multiple PRSU grants and time-based RSU schedules continue to govern vesting.
The explanations enumerate several equity award vintages: PRSUs from 2023 and 2024 with certified performance outcomes and future vesting dates, RSUs from 2023, 2024 and 2025 with specified time-based vesting tranches. These details are material for modeling future dilution and executive pay realization. The Form 4 does not report exercises or derivative transactions, only a sale and outstanding contingent awards, which keeps near-term cash flow and dilution implications limited to the documented vesting schedules.